Pharma in silica launches its first preclinical program

Quebec City, June 1, 2022 - Pharma in silica is initiating the preclinical study of its product candidate OpPacli™ (optimized paclitaxel) against non-small cell lung cancer (NSCLC).

The study is financed by the company's own funds and by grants totaling $650K (Mitacs-Acceleration, NRC-IRAP, IQ Innovation, PSO-Validation, PAEN-MÉI). Professors Nicolas Bertrand and Sébastien Fortin of the CHU de Québec/Université Laval are co-directors of several parts of the study.

The company thanks MITACS, PARI and MÉI for their financial support, as well as Axelys and Québec International for their intermediation.

About Pharma in silica inc.

Laboratoires Pharma in silica inc. is a preclinical-stage pharmaceutical company based in Québec City's Parc Technologique. Since 2019, it has been developing novel treatments for solid cancers (lung, breast, etc.) using OpPacli™, a patented drug nanocarrier. The company is driven by a dynamic group of chemists, pharmacists and managers led by François Arcand, an experienced life sciences entrepreneur (Medicago, Conferences on Plant-made Pharmaceuticals, ERA Biotech). The company established its own research and production facilities and collaborates with oncology experts and world-renowned research centers and has completed the pre-IND/CTA meetings with the FDA and Health Canada.

For more information

François Arcand
President, Pharma in silica inc
514 994 1023 / 418 874-0054 #233
info@pharma-insilica.com

> all news